These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 21183379)

  • 1. Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis.
    Botzoris V; Drosos AA
    Joint Bone Spine; 2011 Jul; 78(4):341-6. PubMed ID: 21183379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic literature review to inform the Portuguese recommendations for the management of Raynaud's phenomenon and digital ulcers in systemic sclerosis and other connective tissue diseases.
    Costa E; Cunha-Santos F; Dourado E; Oliveira D; Falzon L; Romão V; Duarte AC; Cordeiro A; Santiago T; Sepriano A
    ARP Rheumatol; 2024 Jul; 3(Apr-Jun):128-144. PubMed ID: 38306796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raynaud, digital ulcers and calcinosis in scleroderma.
    Nitsche A
    Reumatol Clin; 2012; 8(5):270-7. PubMed ID: 22835924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of cutaneous vascular complications in systemic scleroderma: experience from the German network.
    Herrgott I; Riemekasten G; Hunzelmann N; Sunderkötter C
    Rheumatol Int; 2008 Aug; 28(10):1023-9. PubMed ID: 18320192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
    Gore J; Silver R
    Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356
    [No Abstract]   [Full Text] [Related]  

  • 8. Implications of endothelial shear stress on systemic sclerosis vasculopathy and treatment.
    Frech TM; Machin DR; Murtaugh MA; Stoddard GJ; Bloom SI; Phibbs JV; Donato AJ
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):175-182. PubMed ID: 30277867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of severe digital vasculopathy in systemic sclerosis by colour Doppler sonography is associated with digital ulcers.
    Lüders S; Friedrich S; Ohrndorf S; Glimm AM; Burmester GR; Riemekasten G; Backhaus M
    Rheumatology (Oxford); 2017 Nov; 56(11):1865-1873. PubMed ID: 28340234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital ulcers: overt vascular disease in systemic sclerosis.
    Steen V; Denton CP; Pope JE; Matucci-Cerinic M
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii19-24. PubMed ID: 19487218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the treatment of Raynaud's phenomenon.
    Levien TL
    Vasc Health Risk Manag; 2010 Mar; 6():167-77. PubMed ID: 20448801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
    Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
    Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Raynaud's phenomenon and digital ischemia.
    Herrick AL
    Curr Rheumatol Rep; 2013 Jan; 15(1):303. PubMed ID: 23292819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Digital ulcers in systemic sclerosis: use of endotheline antagonists].
    Mota J; Castellano A; Santiago F; Carvalho P; Madeira AS; Pereira De Moura JM; Nascimento Costa JM
    Acta Med Port; 2011; 24(5):837-42. PubMed ID: 22525638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
    Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
    J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raynaud's phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options.
    Linnemann B; Erbe M
    Vasa; 2016; 45(3):201-12. PubMed ID: 27129065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the pathogenesis and management of Raynaud's phenomenon and digital ulcers.
    Herrick AL
    Curr Opin Rheumatol; 2016 Nov; 28(6):577-85. PubMed ID: 27541182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Algorithms for Systemic Sclerosis According to Experts.
    Fernández-Codina A; Walker KM; Pope JE;
    Arthritis Rheumatol; 2018 Nov; 70(11):1820-1828. PubMed ID: 29781586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.